Catalent Pharma Solutions, Inc. (CTLT)
Dec 18, 2024 - CTLT was delisted (reason: acquired by Novo Holdings)
63.48
0.00 (0.00%)
Inactive · Last trade price
on Dec 17, 2024
Catalent Income Statement
Financials in millions USD. Fiscal year is July - June.
Millions USD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2013 | FY 2012 | FY 2011 | FY 2010 | FY 2009 | 2008 - 2004 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '14 Mar 31, 2014 | Jun '13 Jun 30, 2013 | Jun '12 Jun 30, 2012 | Jun '11 Jun 30, 2011 | Jun '10 Jun 30, 2010 | Jun '09 Jun 30, 2009 | 2008 - 2004 |
| Revenue | 1,813 | 1,800 | 1,695 | 1,532 | 1,480 | 1,562 | Upgrade
|
| Revenue Growth (YoY) | 2.25% | 6.22% | 10.64% | 3.47% | -5.20% | -14.09% | Upgrade
|
| Cost of Revenue | 1,231 | 1,232 | 1,136 | 1,030 | 1,040 | 1,167 | Upgrade
|
| Gross Profit | 582 | 568.6 | 558.6 | 502.1 | 440.9 | 395 | Upgrade
|
| Selling, General & Admin | 328.4 | 326.1 | 316.2 | 261.8 | 248.3 | 269.8 | Upgrade
|
| Research & Development | 16.7 | 14.5 | 16.9 | 26.5 | 21.8 | - | Upgrade
|
| Operating Expenses | 345.1 | 340.6 | 333.1 | 288.3 | 270.1 | 269.8 | Upgrade
|
| Operating Income | 236.9 | 228 | 225.5 | 213.8 | 170.8 | 125.2 | Upgrade
|
| Interest Expense | -165.6 | -203.5 | -183.5 | -165.4 | -164.9 | -192.6 | Upgrade
|
| Currency Exchange Gain (Loss) | -11.9 | -5.7 | 17.1 | - | 25.1 | -3.2 | Upgrade
|
| Other Non Operating Income (Expenses) | 1.5 | -7.3 | -13 | -26.1 | -13.9 | 28.5 | Upgrade
|
| EBT Excluding Unusual Items | 60.9 | 11.5 | 46.1 | 22.3 | 17.1 | -42.1 | Upgrade
|
| Merger & Restructuring Charges | -17.6 | -18.4 | -34.5 | -12.5 | -17.7 | -16.4 | Upgrade
|
| Asset Writedown | -1 | -5.2 | -1.8 | -3.6 | -214.8 | -175.8 | Upgrade
|
| Other Unusual Items | 3.1 | -11.8 | - | -11.6 | - | - | Upgrade
|
| Pretax Income | 45.4 | -23.9 | 18.6 | -5.4 | -215.4 | -234.3 | Upgrade
|
| Income Tax Expense | 41.5 | 24.1 | 16.5 | 23.7 | 21.9 | 17.2 | Upgrade
|
| Earnings From Continuing Operations | 3.9 | -48 | 2.1 | -29.1 | -237.3 | -251.5 | Upgrade
|
| Earnings From Discontinued Operations | 3.4 | 1.2 | -41.3 | -21 | -49.7 | -57.2 | Upgrade
|
| Net Income to Company | 7.3 | -46.8 | -39.2 | -50.1 | -287 | -308.7 | Upgrade
|
| Minority Interest in Earnings | 0.9 | 0.1 | -1.2 | -3.9 | -2.6 | 0.6 | Upgrade
|
| Net Income | 8.2 | -46.7 | -40.4 | -54 | -289.6 | -308.1 | Upgrade
|
| Net Income to Common | 8.2 | -46.7 | -40.4 | -54 | -289.6 | -308.1 | Upgrade
|
| Free Cash Flow | 48.1 | 15.2 | -16.3 | 12.4 | 163.3 | -2 | Upgrade
|
| Gross Margin | 32.10% | 31.58% | 32.96% | 32.78% | 29.78% | 25.29% | Upgrade
|
| Operating Margin | 13.06% | 12.67% | 13.30% | 13.96% | 11.54% | 8.02% | Upgrade
|
| Profit Margin | 0.45% | -2.59% | -2.38% | -3.52% | -19.56% | -19.73% | Upgrade
|
| Free Cash Flow Margin | 2.65% | 0.84% | -0.96% | 0.81% | 11.03% | -0.13% | Upgrade
|
| EBITDA | 383.1 | 380.2 | 355.2 | 329.3 | 288.6 | 258.1 | Upgrade
|
| EBITDA Margin | 21.13% | 21.12% | 20.96% | 21.50% | 19.50% | 16.53% | Upgrade
|
| D&A For EBITDA | 146.2 | 152.2 | 129.7 | 115.5 | 117.8 | 132.9 | Upgrade
|
| EBIT | 236.9 | 228 | 225.5 | 213.8 | 170.8 | 125.2 | Upgrade
|
| EBIT Margin | 13.06% | 12.67% | 13.30% | 13.96% | 11.54% | 8.02% | Upgrade
|
| Effective Tax Rate | 91.41% | - | 88.71% | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.